Cubit Diagnostics

Cubit DiagnosticsCubit Diagnostics
Cubit Diagnostics

Cubit Diagnostics

Developing advanced molecular and immunoassay diagnostic solutions for point-of-care testing.

DR 0.82021Active2Carlsbad, USA
Rate

About

Cubit Diagnostics is a startup focused on developing advanced diagnostic solutions. Their current work includes locking in the design freeze for a molecular CT/NG/TV assay, with plans for clinical studies in the first half of 2027. They are also expanding their immunoassay program, aiming to deliver actionable results at the point of care with rapid turnaround times.
Frequently asked

What does Cubit Diagnostics do?

Cubit Diagnostics is a startup focused on developing advanced diagnostic solutions. Their current work includes locking in the design freeze for a molecular CT/NG/TV assay, with plans for clinical studies in the first half of 2027. They are also expanding their immunoassay program, aiming to deliver actionable results at the point of care with rapid turnaround times.

What is Cubit Diagnostics's revenue?

StartupHub estimates Cubit Diagnostics's annual revenue at $199K (range $121K to $718K, 69% confidence), based on comparable companies in the sector.

What is Cubit Diagnostics's valuation?

StartupHub estimates Cubit Diagnostics's effective valuation at $10.9M (range $7.3M to $17.4M, 23% confidence), based on comparable companies in the sector.

How much funding has Cubit Diagnostics raised?

Cubit Diagnostics has raised a total of $3M in funding. The most recent round on record is SAFE.

Where is Cubit Diagnostics headquartered?

Cubit Diagnostics is headquartered in Carlsbad, California, USA.

When was Cubit Diagnostics founded?

Cubit Diagnostics was founded in 2021.

What industry does Cubit Diagnostics operate in?

Cubit Diagnostics operates in Biotechnology, Healthcare, Diagnostics, MedTech, HealthTech, Point-of-Care Testing.

How many employees does Cubit Diagnostics have?

Cubit Diagnostics has approximately 2 people on record.

HEADCOUNT
2
DOMAIN RATING
0.8
Comments

No comments yet. Be the first to share your take.